So sánh phương pháp

	Thang đo Chất lượng Cuộc sống do Mụn trứng cá (Acne-QoL)	Chỉ số chất lượng cuộc sống da liễu ở trẻ em (cDLQI)	MelasQoL (Thang đo Chất lượng Cuộc sống trong Bệnh Rối loạn Sắc tố Da Mặt)	POEM (Thước đo Eczema Định hướng Bệnh nhân)	Skindex-29 (Bộ công cụ Đo lường Chất lượng Cuộc sống ở Bệnh nhân Da liễu)
Lĩnh vực	Da liễu học	Da liễu học	Da liễu học	Da liễu học	Da liễu học
Họ	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
Năm ra đời	2004	1995	2006	2004	1997
Người khởi xướng	Halvorsen JA et al.	Lewis-Jones MS, Finlay AY	Cestari TF, Hexsel D	Charman CR, Venn AJ, Williams HC	Chren MM, Lasek RJ
Loại	Self-report	Self-report (parent or child proxy)	Self-report	Self-report	Self-report
Công trình gốc	Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011;131(2):363-370.	Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.	Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.
Tên gọi khác	Acne-Q, Acne-Specific QoL	cDLQI, Pediatric DLQI	Melasma-QoL	POEM Score	Skindex, Skindex-QoL
Liên quan	4	3	3	2	1
Tóm tắt	Acne-QoL is a disease-specific, patient-administered quality-of-life measure assessing the psychological and social burden of acne vulgaris. Acne is the most common skin disease in adolescents and young adults and causes substantial psychological distress, depression, anxiety, and social impairment disproportionate to its severity. Multiple versions of Acne-QoL exist (19–24 items); all capture emotional, social, and functional impacts. Acne-QoL is essential in clinical trials and observational studies to ensure treatment efficacy encompasses quality-of-life outcomes.	The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice.	MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes.	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.